Christopher Ellison

Date: 9/9/1997
Title: Cost relief for migraine sufferers

Description:
The migraine-relief drug sumatriptan, marketed under the brand name Imigran, will be available through the Pharmaceutical Benefits Scheme (PBS) on May 1

Date: 13/6/1997
Title: Urgent Royal Jelly analysis continues

Description:
Urgent analysis of the NSW Coroner's request for consideration of royal jelly by the Commonwealth Government is progressing

Date: 10/4/1997
Title: Australia and New Zealand to harmonise drug regulation

Description:
Australia and New Zealand will, over the coming months, actively pursue harmonisation of regulatory requirements for medicinal products and will work in partnership to explore the possibility of establishing a single joint regulatory agency

Date: 10/4/1997
Title: New program for orphan drugs

Description:
Australia will implement a new program to help ensure proper treatment for Australians who suffer from rare disabling or life-threatening diseases

Date: 10/4/1997
Title: Government releases major statement on drug regulation

Description:
The Government today announced major changes to the regulation of Australian medicinal products

Date: 10/4/1997
Title: Government doesn't rule out advertising schedule 3 drugs

Description:
The Government has refused to rule out the advertising of Schedule 3 drugs, despite a recommendation to do so in the recent review of the Therapeutical Goods Administration

Date: 10/4/1997
Title: Improved patient access to complementary medicines

Description:
The Government today released its response to the review of the Therapeutic Goods Administration, detailing a range of initiatives which will elevate the role of complementary medicines in health care in Australia

Date: 10/4/1997
Title: Expansion for TGA headquarters

Description:
The efficiency of Australia's drug regulatory body, the Therapeutic Goods Administration (TGA), is expected to be enhanced with the opening today of an extension to its Canberra headquarters